News

News

July 2025

AAIC Toronto

You can find the article here »


June 2025

New publication by the NTD Study Group:

  • Persistence to Ocrelizumab Compared with Other
  • Disease Modifying Therapies for Multiple Sclerosis
  • Results from the German NeuroTransData Registry

You can find the article here »


May 2025

NTD participation at AAN 2025

The Annual Meeting of the American Academy of Neurology (AAN) 2025


May 2025

Active participation of NTD representative Niloofar Tavakoli at the AI-PROGNOSIS general assembly in Greece

You can find the article here »


April 2025

AD/PD™ 2025 – Science meets progress in Vienna 🇦🇹

This year’s AD/PD™ 2025 congress in Vienna

You can find the article here »


April 2025

🌍 Digital Health Innovation Forum 2025 at the Hasso Plattner Institute (HPI) in Potsdam

You can find the article here »


March 2025

Neurotransdata has founded the non-profit NeuroTransResearch (gGmbH).

Website: www.neurotransresearch.com

You can find the article here »


February 2025

NeuroTrans.App is a digital tool for capturing and visualizing health-related data in neurological diseases. It enables the integration of everyday-relevant assessments and clinical information of the patient for their treating physicians and thus promotes active interaction between doctor and patient during the therapy process – for more transparency and therapeutic success. The app is currently actively used for the headache diary and, as of version 2.2.0 (as of August 5), also features a function for recording acute medication. The NeuroTrans.App has been available since February 7, 2025!

The NeuroTrans.App on Google Play »


2025

Cooperation with Hasso Plattner Institute (HPI)


December 2024

The current issue of the NeuroTransmitter from December 2024 features a publication by the NTD Study Group on the topic of DiGA. The article presents the twelve-month interim results from the elevida project for app-based fatigue treatment.

You can find the article here »


November 2024

NTD highlights of DGN 2024

The NTD team at DGN 2024

See here the highlights of scientific and research results from NTD and partners at DGN 2024

You can find the article here »


October 2024

1st place poster award 2024 DGDM

You can find the article here »


September 2024

Groundbreaking publication by the NTD Study Group in cooperation with Roche International and REWOSO demonstrating for the first time that methodologically transparent and robust patient-level data from randomized clinical trials can be compared with similarly structured real-world data from registries. This opens up new perspectives, e.g. for early evaluation of the relevance of new substances in respective therapeutic landscapes.

You can find the article here »


July 2024

Successful certification of PHREND: PHREND® MDR IIa – Predictive Healthcare for RRMS

The module integrated into DESTINY for personalized, data-driven predictive support of drug treatment decisions in relapsing-remitting multiple sclerosis.

  • CE certified (MDR IIa) & ISO 13485-compliant quality management (July 2024)
  • First predictive tool of its kind certified as MDR IIa
  • Certification valid across Europe
  • Externally validated by IBE of LMU Munich using data from the French OFSEP registry
  • Based on >25,000 real-world data points from the NTD MS registry
  • Modularly expandable to other indications

Read more here »


June 2024

The article "Scoping review of clinical decision support systems for multiple sclerosis management: Leveraging information technology and massive health data" ( https://lnkd.in/ePyAynEq DOI: 10.1111/ene.16363) published by Stanislas Demuth et al

You can find the article here »


June 2024

PHREND for personalized prediction of treatment response in relapsing-remitting multiple sclerosis: a replication study done independently by OFSEP

You can find the article here »


April 2024

NTD District Meeting

From April 18–20, 2024, over 70 participants (board, physicians, medical assistants, database nurses, quality managers) gathered in Frankfurt for the annual in-person meeting.

You can find the article here »


2023

At NTD, we are proud to be a partner in the AI-PROGNOSIS project – because using AI for early detection and personalized Parkinson’s care is not just our job, it's our passion. Together, we empower neurologists with real-world insights to improve lives faster and more precisely.

You can find the article here »


June 2023

The current issue of the NeuroTransmitter from May 2023 features a publication by the NTD Study Group on the topic of DiGAs. The article discusses the first findings from the elevida project.

You can find the article here »


March 2023

In 2023 the NTD will be 15 years old. We look back on many highlights. A key success factor is our digital platform DESTINY. The NTD was and is a pioneer of development and have earned us national and international recognition. Digitization is everywhere now and NTD is at the forefront of this adaptation process.

Also check out our posts on linked in »


09.08.2021

We are pleased that our publication on treatment effectiveness has now appeared in the BMJ open.

The current publications can be found here »


12/04/2021

We are pleased to present you with the current publication on the subject of the Elispot Biomarker Test. You can find it here:

The current publications can be found here »


15/03/2021

We were present at several congresses and were able to present a variety of posters.

The current publications can be found here »


30/11/2020

We were present at several congresses and were able to present a variety of posters.

The current publications can be found here »


25/10/2020

On the 25th of October 2020 „Welt der Wunder“ uploaded a clip about the „Destiny Concept“ to YouTube.

You can view the video here »


10/02/2020

We are happy to announce the paper depicting the framework of the PHREND Module has now been published.

Read more here »


10/12/2019

Phrend is awarded the Business Week's Best of Consulting Award 2019 : „Blue Chip Award“ (category Artificial Intelligence)


22/11/2019

We are pleased to inform you, Destiny was recently honored with 3 awards:

  • ACQ5 Global Awards 2019- Germany, healthtech company of the year
  • GHP- healthcare&pharmaceutical awards 2019
  • German Medical Award 2019

15/11/2019

A research group consisting of members from Xcenda, DAK-Gesundheit, Novartis, university of Bielefeld, DRK Kamillus Klinik and NTD have published a poster at ISPOR congress 2019:

BURDEN OF MULTIPLE SCLEROSIS IN GERMANY – A MATCHED COHORT STUDY USING A LARGE CLAIMS DATABASE

We would like to thank all authors and contributors!


20/10/2019

The fall brought many opportunities for the NTD study group, we presented multiple posters at the ECTRIMS, DGN and at the Schmerzkongress in Mannheim.

You can find them here »